Аллергические реакции при ферментозаместительной терапии детей с мукополисахаридозом, тип II

Мукополисахаридоз, тип II (МПС II; синдром Хантера) — редкое наследственное заболевание, вызванное изменениями в структуре гена IDS и связанным с ними дефицитом лизосомного фермента идуронат-2-сульфатазы (I2S). Основой лечения детей с МПС II является ферментозаместительная терапия (ФЗТ) с рекомбинантной человеческой I2S. Одной из основных проблем ФЗТ является развитие аллергических, в том числе тяжелых анафилактических, реакций на рекомбинантные ферменты. В статье рассмотрены особенности инфузионных реакций гиперчувствительности при ФЗТ, описаны патогенез, диагностические критерии и алгоритм лечения анафилаксии. Обоснована необходимость дальнейших исследований аллергических инфузионных реакций у детей при ФЗТ.

1. Sestito S, Ceravolo F, Grisolia M, et al. Profile of idursulfase for the treatment of Hunter syndrome. Research and Reports in Endocrine Disorders. 2015;5:79–90. doi: 10.2147/RRED.S64347

2. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8(8):465–473. doi: 10.1097/01.gim.0000232477.37660.fb

3. Sohn YB, Cho SY, Park SW, et al. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). Orphanet J Rare Dis. 2013;8:42. doi: 10.1186/1750-1172-8-42

4. Мукополисахаридоз тип II: клинические рекомендации / Союз педиатров России; Ассоциация медицинских генетиков. — МЗ РФ; 2021. — 79 с. Доступно по: https://cr.minzdrav.gov.ru/recomend/392_2. Ссылка активна на 11.12.2021.

5. Kim C, Seo J, Chung Y, et al. Comparative study of idursulfase beta and idursulfase in vitro and in vivo. J Hum Genet. 2017;62(2): 167–174. doi: 10.1038/jhg.2016.133

6. Miebach E. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders. Int J Clin Pharmacol Ther. 2009; 47 Suppl 1:S100–S106. doi: 10.5414/cpp47100

7. Burton BK, Whiteman DA. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2011;103(2):113–120. doi: 10.1016/j.ymgme.2011.02.018

8. Brooks DA, Kakavanos R, Hopwood JJ. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med. 2003;9(10):450–453. doi: 10.1016/j.molmed.2003.08.004

9. Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy. 2014;69(4):420–437. doi: 10.1111/all.12350

10. Rasheed S, Nelson-Rees WA, Toth EM, et al. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer. 1974;33(4):1027–1033. doi: 10.1002/1097-0142(197404)33:4<1027::aid-cncr2820330419>3.0.co;2-z

11. Lai T, Yang Y, Ng SK. Advances in Mammalian cell line development technologies for recombinant protein production. Pharmaceuticals (Basel). 2013;6(5):579–603. doi: 10.3390/ph60505799

12. Vojta A, Samaržija I, Bočkor L, Zoldoš V. Glyco-genes change expression in cancer through aberrant methylation. Biochim Biophys Acta. 2016;1860(8):1776–1785. doi: 10.1016/j.bbagen.2016.01.002

13. D’Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment. Int J Mol Sci. 2020;21(4):1258. doi: 10.3390/ijms21041258

14. Chung YK, Sohn YB, Sohn JM, et al. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome. Glycoconj J. 2014;31(4):309–315. doi: 10.1007/s10719-014-9523-0

15. Ngu LH, Ong Peitee W, Leong HY, Chew HB. Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II. Mol Genet Metab Rep. 2017;12: 28–32. doi: 10.1016/j.ymgmr.2017.05.002

16. Kim J, Park MR, Kim DS, et al. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome. Allergy. 2013;68(6):796–802. doi: 10.1111/all.12155

17. Okuyama T, Tanaka A, Suzuki Y, et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccha ridosis II, MPS II). Mol Genet Metab. 2010;99(1):18–25. doi: 10.1016/j.ymgme.2009.08.006

18. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol. 2007;7(5):365–378. doi: 10.1038/nri2072

19. Oettgen HC. Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J Allergy Clin Immunol. 2016;137(6):1631–1645. doi: 10.1016/j.jaci.2016.04.009

20. Hamilton RG, MacGlashan DW Jr, Saini SS. IgE antibodyspecific activity in human allergic disease. Immunol Res. 2010; 47(1–3):273–284. doi: 10.1007/s12026-009-8160-3

21. Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol. 2007;120(1 Suppl):S2–S24. doi: 10.1016/j.jaci.2007.05.001

22. Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S116–S125. doi: 10.1016/j.jaci.2009.08.028

23. Khodoun M, Strait R, Orekov T, et al. Peanuts can contribute to anaphylactic shock by activating complement. J Allergy Clin Immunol. 2009;123(2):342–351. doi: 10.1016/j.jaci.2008.11.004

24. Khodoun MV, Strait R, Armstrong L, et al. Identification of markers that distinguish IgE-from IgG-mediated anaphylaxis. Proc Natl Acad Sci U S A. 2011;108(30):12413–12418. doi: 10.1073/pnas.1105695108

25. Arias K, Chu DK, Flader K, et al. Distinct immune effector pathways contribute to the full expression of peanut-induced anaphylactic reactions in mice. J Allergy Clin Immunol. 2011;127(6):1552–1561. e1. doi: 10.1016/j.jaci.2011.03.044

26. de Silva D, Singh C, Muraro A, et al. Diagnosing, managing and preventing anaphylaxis: Systematic review. Allergy. 2021; 76(5):1493–1506. doi: 10.1111/all.14580

27. Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13(10):100472. doi: 10.1016/j.waojou.2020.100472

28. Ильина Н.И., Заболотских И.Б., Астафьева Н.Г. и др. Анафилактический шок. Клинические рекомендации Российской ассоциации аллергологов и клинических иммунологов и Общероссийской общественной организации «Федерация анестезиологов и реаниматологов» // Вестник интенсивной терапии им. А.И. Салтанова. — 2020. — № 3. — С. 15–26. doi: 10.21320/1818-474X-2020-3-15-26

29. Аллергология и иммунология / под ред. Л.С. Намазовой-Барановой, А.А. Баранова, Р.М. Хаитова. — М.: Союз педиатров России; 2020.

30. Lieberman P, Nicklas R, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 Update. J Allergy Clin Immunol. 2010;126(3):477–480.e42. doi: 10.1016/j.jaci.2010.06.022

31. Sala-Cunill V. Cardona Biomarkers of anaphylaxis, beyond tryptase. Curr Opin Allergy Clin Immunol. 2015;15(4):329–336. doi: 10.1097/ACI.0000000000000184

32. Serrano CD, Gomez JF. Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (Hunter syndrome). J Investig Allergol Clin Immunol. 2011;21(7):571–572.

33. Кручина Т.К., Бручиков К.В., Новик Г.А. Опыт применения препарата идурсульфаза бета у ребенка с мукополисахаридозом II типа: клинический случай // Вопросы современной педиатрии. — 2020. — Т. 19. — № 5. — С. 364–370. doi: 10.15690/vsp.v19i5.2212

34. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017;140(2):335–348. doi: 10.1016/j.jaci.2017.06.003

35. Matheu V, Franco A, Pérez E, et al. Omalizumab for drug allergy. J Allergy Clin Immunol. 2007;120(6):1471–1472; author reply 1472–1473. doi: 10.1016/j.jaci.2007.07.03

36. Mishra S, Connors L, Tugwell B. Role of omalizumab in insulin hypersensitivity: a case report and review of the literature. Diabet Med. 2018;35(5):663–666. doi: 10.1111/dme.13591

37. Cavelti-Weder C, Muggli B, Keller C, et al. Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy. Diabetes Care. 2012;(6):e41. doi: 10.2337/dc12-0115

38. Arroabarren E, Aznal E, Anda M, Sánchez-Valverde F. Anaphylaxis after Elosulfase A infusion: Omalizumab as coadyuvant for enzyme replacement therapy desensitization. Pediatr Allergy Immunol. 2019;30(4):491–494. doi: 10.1111/pai.13049